2019 SITC: Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms

Checkpoint inhibitor therapy has demonstrated meaningful antitumor activity for many patients, though the majority fail to achieve complete response. Thus, it is of particular interest to identify biomarkers and mechanisms that promote positive response to immunotherapy. In the present study, we apply our comprehensive tumor immunogenomics platform (ImmunoID NeXT), integrating data from the tumor, tumor microenvironment and immune system to create a comprehensive biological signature of patient response to therapy.

Download